IFF_HS_Our-Products_HOWARU_Signature-Strains_Strains_NCFM

HOWARU® NCFM®

HOWARU® NCFM®

Lactobacillus acidophilus NCFM®

Image credits: © IFF, Finland, 2021 (FESEM imaging VTT)

HOWARU® Lactobacillus acidophilus NCFM® was first isolated from a human source in the early 1970s. NCFM® has been safely investigated and published in more than 470 scientific publications, including more than 100 human clinical trial publications, as a single entity and in combination with other probiotics and prebiotics.

Product Information:
  • 330+ preclinical publications
  • ~105 clinical publications

Health Benefits:
Digestive-HealthDigestiveImmune-HealthImmune

NCFM® BLENDS

Learn more about IFF Health Sciences’ NCFM® blends.

d068b70b62be0324dc4c23d5d77a3a96c39d4691_cropped3

HOWARU® GI Complete

csm_Products_HOWARU-Dophilus_Banner_Flipped_9cb86796f0_3c83576801f29bef42046125f93285ce.jpg

HOWARU® Dophilus

IFF_HS_Our-Products_HOWARU-Protect-Kids_1_Edit

HOWARU® Protect Kids

IFF_HS_Our-Products_HOWARU-Protect-Sport_1

HOWARU® Protect Sport

Howaru-Restore-Cropped2

HOWARU® Restore

NCFM® CLINICAL STUDIES & PUBLICATIONS

It has been studied alongside other strains as a component of the HOWARU® Restore blend (NCFM®, Lpc-37®, Bi-07®, Bl-04®) for digestive health and with Bi-07® for early life development in the HOWARU® Protect Kids and HOWARU® Protect Sport blends.¹⁻² The subjects in these trials have ranged from infants to aging populations (from 6 months to over 65 years of age).

It has a long history of safe use, is well suited for intestinal survival, and has strong adhesion to intestinal cell lines.³⁻⁴

BSS02330-Enhanced-NR

Health Benefit Areas

Each strain’s health benefits are supported by recommended daily doses and peer-reviewed clinical studies.

Click on a Health Benefit to see more studies and learn more.

  1. Supporting Daily Dose: 17B CFU (equal parts) Bl-04®, NCFM®, Bi-07®, Lpc-37®
    Study Reference: Ouwehand AC, et al. Vaccine. 2014;32(4):458-463
  2. Supporting Daily Dose: 1-10B CFU NCFM®
    Study Reference: Lyra A, et al. World J Gastroenterol. 2016; 22(48):10631-10642.
  3. Supporting Daily Dose: 10B CFU Total Bi-07®, Bl-04®, NCFM®, Lpc-37®
    Study Reference: van Zanten G, et al. Microorganisms. 2024; 12(4),796.
LEARN MORE

  1. Supporting Daily Dose: 10B CFU (equal parts) NCFM® and Bi-07®
    Study Reference: Leyer GJ, et al. Pediatrics. 2009;124(2):e172-179.
  2. Supporting Daily Dose: 10B CFU (equal parts) Bi-07® and NCFM®
    Study Reference: West N, et al. Clinical Nutrition. 2014;33(4):581-587.
  3. Supporting Daily Dose: 10B CFU (equal parts) NCFM® and Bi-07®
    Study Reference: Bergmann K, et al. World Allergy Organ J. 2021;14(1):100494.
LEARN MORE

References:1. Ouwehand AC et al.;Vaccine. 2014; 2. Leyer GJ et l.;Pediatrics. 2009; 3. Andreasen AS et al.; Br J Nutr. 2010; 4. Kleeman EG et al..J Dairy Sci. 1982